the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Ministery of International Trade and Industry, 1-3, Higaski 1-chrome, Tsukuba-shi Ibaraki-ken, 305, Japan.

IN THE CLAIMS:

Please cancel claims 16 – 23 without prejudice or disclaimer for filing in a continuing application. Kindly amend the claims as follows:

15. (Once amended) A method of treating a patient [subject] having cachexia [a disease] caused by interleukin-6 (IL-6) production comprising administering to said patient [subject] a therapeutically effective amount of an antibody to an IL-6 receptor in a pharmaceutically acceptable carrier to treat said cachexia and wherein the therapeutically effective amount blocks signal transduction by IL-6 and inhibits the binding of IL-6 to the IL-6 receptor.

25. (Once amended) The method according to claim 24, wherein said monoclonal antibody is the PM-1 antibody produced by [hyridoma] hybridoma PM-1, accession number FERM BP-2998.

28. (Once amended) The method according to claim 27, wherein said humanized murine monoclonal antibody to an IL-6 receptor is a humanized PM-1 antibody, wherein the PM-1 antibody prior to humanization is produced by [hyridoma] hybridoma PM-1, accession number FERM BP-2998.

REMARKS

Claims 15-28 are presently pending in this application. Claims 16-23 are cancelled. Claims 15, 25 and 28 are amended. Support for the amendment to claim 15 is found in the paragraph bridging pages 3 - 4 of the specification for the recitation of "the therapeutically effective amount blocks signal transduction by IL-6 and inhibits the binding of IL-6 to the IL-6 receptor" and is found on page 9, lines 22 and 25 for the word "patient." Applicants